BellaSeno Presents Novel Production Workflow for Customized, 3D-Printed Bone Scaffolds
October 30, 2023 05:00 ET
|
AKAMPION
Presentation at the German Congress of Orthopaedics and Traumatology (DKOU)Treatment of large segmental bone defects with resorbable scaffoldsLeading-edge workflow for the design and manufacturing of...
ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002
October 24, 2023 04:00 ET
|
AKAMPION
Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, as monotherapy and in combination with pembrolizumab in advanced solid tumorsTrial overview presented at ESMO Congress...
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA
October 17, 2023 04:00 ET
|
AKAMPION
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors ...
Dopavision Reports Successful Completion of Enrollment for MyopiaX-1 Trial
September 26, 2023 04:00 ET
|
AKAMPION
- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected in Q1/ 2024 with study completion planned...
Cellbox Solutions Submits Device Master File (DMF) to the U.S. FDA
September 25, 2023 04:00 ET
|
AKAMPION
Submission represents an important step towards establishing the Cellbox Live Shipment Technology as a new standard for warm chain logistic in the cell therapy sectorCellbox customers can now...
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA® (pembrolizumab)
September 19, 2023 04:00 ET
|
AKAMPION
YONGIN, South Korea, September 19, 2023 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative...
ImmunOs Therapeutics Appoints Dr. Constanze Guenther as Senior Vice President, CMC and Technical Development
September 19, 2023 04:00 ET
|
AKAMPION
- Former Novartis Executive Director brings significant expertise in manufacturing, operations, and technical development Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA –...
Thermosome Establishes High-Profile Clinical Advisory Board
September 19, 2023 04:00 ET
|
AKAMPION
Leveraging the transformative potential of TSL-based tumor targeting Supporting the progress of Thermosome's clinical candidate THE001 Munich, Germany – September 19, 2023 – Thermosome, a drug...
BellaSeno Reports Positive One-Year Patient Follow-Up Data for Resorbable Breast and Pectus Excavatum Scaffolds
September 05, 2023 04:00 ET
|
AKAMPION
Key milestone for novel, resorbable breast / pectus reconstruction implants Leipzig, Germany, September 5, 2023 – BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable...
TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing
July 06, 2023 04:00 ET
|
AKAMPION
Ongoing Phase IIb study expands to arm B5-year results of phase I study confirm efficacy and safety of novel immune-tolerance inducing cell therapy in organ transplantationSecond closing of Series A...